Statin Initiation Cuts Mortality in Older Adults With Chronic Kidney Disease
By Lori Solomon HealthDay Reporter
FRIDAY, Jan. 5, 2024 -- Statin initiation may lower the risk for mortality and major adverse cardiovascular events (MACE) in older adults with chronic kidney disease (CKD) and no prior atherosclerotic cardiovascular disease (ASCVD), according to a study published online Dec. 6 in JAMA Network Open.
Odeya Barayev, M.D., from Ben Gurion University of the Negev in Be'er Sheva, Israel, and colleagues evaluated whether new statin use was associated with a lower risk for mortality or MACE among adults older than 65 years with CKD stages 3 to 4 and no history of ASCVD. The analysis included data from 14,828 U.S. veterans.
The researchers found that risk for all-cause mortality was lower among participants initiating statins versus noninitiators (hazard ratio, 0.91; 95 percent confidence interval, 0.85 to 0.97). There was a trend observed toward a lower risk for MACE (hazard ratio, 0.96; 95 percent confidence interval, 0.91 to 1.02). Results persisted in prespecified subgroup analyses.
"Among U.S. veterans older than 65 years with CKD stages 3 to 4 and no prior ASCVD, statin initiation was associated with a lower risk of all-cause mortality compared with no statin initiation. Results should be confirmed in a randomized clinical trial," the authors write. "However, until such trials are completed, these data argue against withholding or deprescribing statins for primary prevention in older patients with CKD stages 3 to 4."
Several authors disclosed financial ties to Novartis; one author disclosed ties to Anthos Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in...
Leukocyte Glucose Index, Arteriovenous Fistula Failure Linked in ESKD
MONDAY, April 22, 2024 -- For patients with end-stage kidney disease (ESKD), a high preoperative leukocyte glucose index (LGI) is associated with arteriovenous fistula (AVF)...
Risk Prediction Model Accurate for Chronic Kidney Disease
FRIDAY, April 19, 2024 -- For individuals with moderate-to-severe chronic kidney disease (CKD), a model, KDpredict, can accurately predict the risk for kidney failure and death...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.